Chapter 50. Evidence-Based Review of Therapies in Multiple Myeloma

  1. Mark A. Crowther MD, MSc, FRCPC Professor Division Director3,4,
  2. Jeff Ginsberg MD, FRCPC Professor5,
  3. Holger J. Schünemann MD, PhD, MSc, FACP, FCCP Professor6,7,
  4. Ralph M. Meyer MD, FRCPC Director Professor8,9 and
  5. Richard Lottenberg MD, FACP Professor10
  1. Michael Sebag MD, PhD, FRCPC1 and
  2. A. Keith Stewart MBCHB, FRCPC, FACP2

Published Online: 4 FEB 2009

DOI: 10.1002/9781444300857.ch50

Evidence-Based Hematology

Evidence-Based Hematology

How to Cite

Sebag, M. and Stewart, A. K. (2008) Evidence-Based Review of Therapies in Multiple Myeloma, in Evidence-Based Hematology (eds M. A. Crowther, J. Ginsberg, H. J. Schünemann, R. M. Meyer and R. Lottenberg), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444300857.ch50

Editor Information

  1. 3

    Division of Hematology, McMaster University, Hamilton, Ontario, Canada

  2. 4

    St. Joseph's Hospital, Hamilton, Ontario, Canada

  3. 5

    Department of Medicine, McMaster University, Hamilton, Canada

  4. 6

    CLARITY Research Group, Department of Epidemiology, Italian National Cancer Institute Regina Elena, Rome, Italy

  5. 7

    McMaster University, Hamilton, Canada

  6. 8

    National Cancer Institute of Canada, Clinical Trials Group, Edith Eisenhauer Chair in Clinical Cancer Research, Queen's University, Kingston, Ontario, Canada

  7. 9

    Departments of Oncology and Medicine, Queen's University, Kingston, Ontario, Canada

  8. 10

    Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, Florida, USA

Author Information

  1. 1

    Mayo Clinic Arizona, Scottsdale, Arizona, USA

  2. 2

    College of Medicine, Mayo Clinic, Scottsdale, Arizona, USA

Publication History

  1. Published Online: 4 FEB 2009
  2. Published Print: 27 JUN 2008

ISBN Information

Print ISBN: 9781405157476

Online ISBN: 9781444300857

SEARCH

Keywords:

  • Multiplemyeloma (MM) - second most common hematological malignancy in adults;
  • literature-search strategy and inclusions;
  • therapies in multiple myeloma;
  • Phase III Trials comparing stem cell transplantation with conventional chemotherapy;
  • high dose therapy followed by stem cell transplant and improved outcomes;
  • lactate dehydrogenase (LDH);
  • bortezomib superior to dexamethasone in relapsed/refractory myeloma;
  • lenalidomide role in patients with relapsed or refractory myeloma

Summary

This chapter contains sections titled:

  • Questions

  • Literature-search strategy and inclusions

  • In patients who are to undergo autologous transplantation as initial therapy is dexamethasone with thalidomide superior to dexamethasone alone as initial therapy for untreated multiple myeloma?

  • Does the addition of thalidomide to melphalan and prednisone improve outcomes in untreated patients?

  • Recommendation

  • Does high dose therapy followed by stem cell transplant improve outcomes compared with conventional therapy?

  • Is bortezomib superior to dexamethasone in relapsed/refractory myeloma?

  • Recommendations

  • What is the role of lenalidomide in patients with relapsed or refractory myeloma?

  • References